<DOC>
	<DOCNO>NCT01649804</DOCNO>
	<brief_summary>This extension study WA19926 ass long-term safety efficacy RoActemra/Actemra ( tocilizumab ) treatment participant rheumatoid arthritis . Participants complete core study WA19926 eligible participate . Participants receive RoActemra/Actemra 8 mg/kg intravenously every 4 week . The anticipated time study drug 104 week .</brief_summary>
	<brief_title>A Long-Term Safety Extension Study WA19926 Participants With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult participant , &gt; /=18 year age complete core study WA19926 accord investigator may benefit RoActemra/Actemra treatment No current recent adverse event laboratory find prevent use study drug dose baseline Receiving treatment outpatient basis Females pregnant Participants prematurely withdraw core study WA19926 reason Treatment investigational drug since last administration study drug core study WA19926 Treatment antitumor necrosis ( TNF ) , antiinterleukin 1 agent Tcell costimulation modulator since last administration study drug core study WA19926 Immunization live/attenuated vaccine since last administration study drug core study WA19926 Diagnosis since last WA19926 visit rheumatic autoimmune disease inflammatory joint disease rheumatoid arthritis Abnormal laboratory value</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>